RxDoctor Payments DataLook up a doctor →

Tony Das, MD

Interventional Cardiology · Dallas, TXNPI 1295734408

Payments from drug & device makers

$262,635in general payments, 2019–2025

Across 455 payments — averaging $577.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acarix USA Inc.$89K
  • Boston Scientific$62K
  • Cordis US CORP.$37K
  • Angiodynamics, Inc.$27K
  • Elucid Bioimaging Inc$16K
  • Medtronic$11K
  • plus $21K from 54 others

What the payments were for

  • Consulting fees$161,75886%
  • Speaking & faculty fees$2,0001%
  • Travel & lodging$6,5183%
  • Food & beverage$17,0919%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Acarix USA Inc.11$89,096
Boston Scientific48$61,842
Cordis US CORP.11$36,723
Angiodynamics, Inc.16$26,940
Elucid Bioimaging Inc1$16,000
Medtronic(2 entities)49$11,418
Biotronik Inc.13$4,103
Cardinal Health 200 LLC2$2,500
Endologix LLC13$1,821
Heartflow, Inc.23$1,116
Silk Road Medical, Inc.3$1,085
Cardiovascular Systems Inc.7$957
Novartis47$881
Abbott15$837
Inspiremd Ltd3$612
Cleerly, Inc.8$559
Shockwave Medical, Inc4$483
W. L. Gore & Associates, Inc.3$468
Edwards Lifesciences4$416
Bard Peripheral Vascular, Inc.4$381
Inari Medical, Inc.16$369
Pfizer18$361
Amplitude Vascular Systems, Inc.1$278
Amgen15$276
Johnson & Johnson15$259
E.r. Squibb & Sons, L.L.C.12$255
Surmodics, Inc.2$229
Arineta, Inc3$200
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)6$200
Amarin Pharma, Inc.9$184
Galderma Laboratories, L.p.5$165
Merck8$136
Boehringer Ingelheim6$125
GE HealthCare2$124
Abiomed1$121
Veryan Medical Incorporated1$115
Esperion Therapeutics, Inc.6$106
Sanofi-aventis U.S. LLC5$94
Philips North America LLC2$92
Lexicon Pharmaceuticals, Inc.4$81
Tactile Systems Technology Inc5$74
Impulse Dynamics (USA) Inc.2$50
Biosense Webster, Inc.1$45
Bolton Medical Inc2$43
Novo Nordisk2$39
Astellas Pharma US Inc2$39
Getinge USA Sales, LLC1$27
Inspire Medical Systems, Inc.1$25
Contego Medical, Inc1$25
Chiesi USA, Inc.2$25
Vivaquant Inc, Dba Rhythm Express2$22
Coala Life Inc1$21
Siemens Medical Solutions USA, Inc.1$20
Osprey Medical Inc1$19
Vital Connect, Inc1$19
Avinger Inc.1$18
Scpharmaceuticals Inc.1$18
BD1$17
Irhythm Technologies, Inc.1$17
Intact Vascular, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$262,635 in reported general payments places this provider in the 90th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$1,821,176
Medicare patients
1,426
Services billed
13,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban418$441,449
EntrestoSacubitril/Valsartan164$198,687
Repatha SureclickEvolocumab52$58,420
FarxigaDapagliflozin Propanediol53$50,772
XareltoRivaroxaban39$42,660
Praluent PenAlirocumab37$34,661
BrilintaTicagrelor18$20,110
VascepaIcosapent Ethyl27$15,978
JardianceEmpagliflozin12$14,994
Ranolazine ErRanolazine110$13,221
MultaqDronedarone Hcl14$10,796
ClopidogrelClopidogrel Bisulfate588$7,520
Metoprolol Succinate540$7,156
Prasugrel Hcl23$5,956
Ezetimibe72$3,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$361$441,449418 claims
NovartisEntresto$881$198,687164 claims
Johnson & JohnsonXarelto$259$42,66039 claims
Boehringer IngelheimJardiance$125$14,99412 claims
Sanofi-aventis U.S. LLCMultaq$94$10,79614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →